Skip to content
Home/GPs/Rosetta Capital
Rosetta Capital

Rosetta Capital

Haddenham, United Kingdom·Founded 2000··rosettacapital.com

Rosetta Capital Limited is a UK life-sciences and medical-device venture capital firm incorporated in 2000 (originally Bioscience Managers Limited) and headquartered in Haddenham, Buckinghamshire. Authorised and regulated by the Financial Conduct Authority (FRN 196844), it invests globally through direct secondary transactions, acquiring baskets of late-stage therapeutic, diagnostic and medical-device assets from venture funds, corporates and listed trusts seeking liquidity. Over 20-plus years the firm has completed 50-plus venture investments and currently manages Funds IV and V.

AUM
Funds
2
vintages 2013–2021
Portfolio
16
Exits
4
SectorsHealthcare

Key facts

HQHaddenham, United Kingdom
Founded2000
Employees6+

Recent exits

Inivata
Inivata
HealthTech2021 · <1yr hold
Biosergen
Biotech2021 · 8yr hold
Modus Therapeutics
Modus Therapeutics
Biotech2021 · 8yr hold
Aprea Therapeutics
Biotech2019 · 6yr hold

Coverage notes

2 funds tracked, 20 portfolio companies (16 active · 4 realized). Verified weekly from public filings and deal announcements.

Sector breakdown

20 companies
Biotech
15 · 75%
MedTech
3 · 15%
HealthTech
1 · 5%
Pharma
1 · 5%

Funds & portfolio

Every fund Rosetta Capital has raised, with its portfolio companies. Hand-checked from public filings.

2 funds
Rosetta Capital VSecondaries
2021 · 5yr€57M6 active · 1 realized

Unrealized

6 held
BiotechIreland· Entry 2021
Immunocore
ImmunocoreActive
BiotechUK· Entry 2021
BiotechUK· Entry 2021
BiotechUK· Entry 2021
BiotechUK· Entry 2021
ReNeuron
ReNeuronActive
BiotechUK· Entry 2021

Realized

1 exit
Inivata
InivataExited 2021
HealthTechUK· Entry 2021
Trade Saleto
Rosetta Capital IVSecondaries
2013 · 13yr€30M10 active · 3 realized

Unrealized

10 held
PharmaSweden· Entry 2013
AxelarActive
BiotechSweden· Entry 2013
ClanotechActive
BiotechSweden· Entry 2013
Dilafor
DilaforActive
BiotechSweden· Entry 2013
MedTechSweden· Entry 2013
NeoDynamicsActive
MedTechSweden· Entry 2013
NovaSAIDActive
BiotechSweden· Entry 2013
PergamumActive
BiotechSweden· Entry 2013
Promimic
PromimicActive
MedTechSweden· Entry 2013
BiotechSweden· Entry 2013

Realized

3 exits
Aprea TherapeuticsExited 2019
BiotechSweden· Entry 2013
IPO
BiosergenExited 2021
BiotechSweden· Entry 2013
IPO
Modus Therapeutics
Modus TherapeuticsExited 2021
BiotechSweden· Entry 2013
IPO
Track Rosetta Capital

Saved GPs appear in your watchlist, one click from your workspace.

About Rosetta Capital

Rosetta Capital is an alternative investment platform with capital deployed across 1 active fund vehicles, headquartered in London. The firm deploys capital across European mid and small-cap businesses spanning software, consumer, TMT, financials, healthcare and business services.

Investment thesis

The platform combines complementary investment strategies, deploying capital across software, consumer, TMT, financials, healthcare and business services businesses in the United Kingdom and broader European market. Multi-strategy capital deployment enables flexibility across the business lifecycle, with the partnership culture supporting management teams through growth, transmission and selective M&A across multiple fund vintages and asset classes.

Recent activity

Realised exits across the current platform vintages remain limited, with the portfolio in active deployment and value-creation phase. The platform tracks 1 dedicated investment vehicle, 15 active portfolio companies and 0 realised exits across the strategy's history. Detailed buyer names and multiple data available on Pro at €29/month.

Get the full picture on Rosetta Capital.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Save this GP to your watchlist
Saved searches that re-run your sourcing filters in one click
Geography breakdown across 3 geographies
Exit buyers and MOIC on every realized deal (Pro)
Export, compare GPs side by side (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Last updated August 2026 · Sourced from public filings · Report an issue